inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 11 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 11 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: adult ≥18 years of age at the time of enrolment hospitalized patients with any of the following criteria: the presence of pulmonary rales/crackles on clinical exam or spo2 ≤ 94% on room air or requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation a time between onset of symptoms and randomization of less than 11 days a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization contraceptive use by men or women. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: adult ≥18 years of age at the time of enrolment hospitalized patients with any of the following criteria: the presence of pulmonary rales/crackles on clinical exam or spo2 ≤ 94% on room air or requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation a time between onset of symptoms and randomization of less than 11 days a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization contraceptive use by men or women. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 11 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 11 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 9 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: 1. adult ≥18 years of age at the time of enrolment 2. hospitalized patients with any of the following criteria: 1. the presence of pulmonary rales/crackles on clinical exam or 2. spo2 ≤ 94% on room air or 3. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. a time between onset of symptoms and randomization of less than 9 days 4. a positive sars-cov-2 pcr performed on a np swab within the 5 days preceding randomization 5. the result of a rapid antigen test performed on a np swab within the 6 hours preceding randomization 6. contraceptive use by men or women. 1. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue for 90 days following administration of imp. 2. female participants: women of child-bearing potential must agree to use contraception for 365 days following administration of imp

inclusion criteria: - adult ≥18 years of age at time of enrolment. - has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - hospitalized patients with illness of any duration, and at least one of the following: - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air, or - acute respiratory failure requiring mechanical ventilation and/or supplemental oxygen. - women of childbearing potential must agree to use contraception for the duration of the study. acceptable birth methods control are listed in section 7.3

inclusion criteria: - adult ≥18 years of age at time of enrolment. - has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - hospitalized patients with illness of any duration, and at least one of the following: - clinical assessment (evidence of rales/crackles on exam) and spo2 ≤ 94% on room air, or - acute respiratory failure requiring mechanical ventilation and/or supplemental oxygen. - women of childbearing potential must agree to use contraception for the duration of the study. acceptable birth methods control are listed in section 7.3